Personal CFO Solutions LLC Takes $224,000 Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Personal CFO Solutions LLC bought a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,230 shares of the biopharmaceutical company’s stock, valued at approximately $224,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in ACAD. SG Americas Securities LLC raised its position in shares of ACADIA Pharmaceuticals by 380.3% in the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after buying an additional 1,966,607 shares in the last quarter. Iron Triangle Partners LP acquired a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at approximately $11,535,000. Eventide Asset Management LLC acquired a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at approximately $8,882,000. Fred Alger Management LLC raised its position in shares of ACADIA Pharmaceuticals by 17.8% in the 3rd quarter. Fred Alger Management LLC now owns 3,186,389 shares of the biopharmaceutical company’s stock valued at $49,007,000 after buying an additional 481,950 shares in the last quarter. Finally, Burney Co. acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at approximately $6,953,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ ACAD opened at $17.19 on Wednesday. The company has a market capitalization of $2.87 billion, a P/E ratio of 22.04 and a beta of 0.43. ACADIA Pharmaceuticals Inc. has a 52-week low of $14.15 and a 52-week high of $20.68. The company’s 50 day moving average price is $18.51 and its 200-day moving average price is $16.95.

Insider Transactions at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the transaction, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. The trade was a 21.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 6,167 shares of company stock worth $114,583. Company insiders own 28.30% of the company’s stock.

Wall Street Analysts Forecast Growth

ACAD has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $23.00 to $20.00 in a report on Friday, January 3rd. StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target on the stock. Eight analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.